How to manage adverse effects associated with Sodium-Glucose Linked Transporter 1 (SGLT-1) inhibitors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Managing Adverse Effects of SGLT-1 Inhibitors

SGLT-1 inhibitors primarily cause gastrointestinal adverse effects (particularly diarrhea), increase the risk of euglycemic diabetic ketoacidosis, and can interfere with oral correction of hypoglycemia. 1

Primary Adverse Effects

Gastrointestinal Effects

  • Diarrhea is the most common adverse effect of SGLT-1 inhibition, occurring because unabsorbed glucose remains in the intestinal lumen, creating an osmotic effect. 1, 2
  • The dual SGLT1/SGLT2 inhibitor sotagliflozin demonstrated diarrhea rates of 6.1% versus 3.4% with placebo. 3
  • This occurs because SGLT-1 is the primary transporter for glucose absorption in the gastrointestinal tract, and its inhibition blocks intestinal glucose uptake. 4, 5

Volume Depletion

  • SGLT-1 inhibition can lead to volume depletion through both gastrointestinal fluid losses (from diarrhea) and the combined diuretic effect when SGLT-2 is also inhibited. 1
  • Maintain adequate hydration during therapy, particularly when initiating treatment or during intercurrent illness. 6, 7

Serious Adverse Effects

Euglycemic Diabetic Ketoacidosis (DKA)

  • SGLT-1 inhibition (particularly in dual SGLT1/SGLT2 inhibitors) increases the risk of euglycemic DKA, presenting with blood glucose <250 mg/dL despite metabolic acidosis (pH <7.3) and elevated ketones. 6, 1
  • The mechanism involves altered insulin-glucagon ratio, decreased insulin secretion, and relative increase in glucagon, creating a hormonal environment promoting ketogenesis despite normal glucose levels. 6
  • Sotagliflozin showed increased severe hypoglycemia rates (1.5% vs. 0.3% with placebo) and DKA risk (RR 3.11; 95% CI, 2.11-4.58) in meta-analyses. 3, 8

Prevention strategies for euglycemic DKA:

  • Discontinue SGLT inhibitors 3-4 days before elective surgery (canagliflozin, dapagliflozin, empagliflozin ≥3 days; ertugliflozin ≥4 days). 6, 7
  • Avoid prolonged fasting periods and ensure adequate hydration. 6, 7
  • Educate patients on DKA triggers: insulin dose reductions, low caloric/fluid intake, intercurrent illness, alcohol consumption. 6, 4
  • Monitor for symptoms even with normal glucose: malaise, nausea, vomiting, abdominal pain. 6, 7
  • Consider glucose-containing IV fluids during unavoidable prolonged fasting. 6, 7

Hypoglycemia Management Interference

  • SGLT-1 inhibition blocks intestinal glucose absorption, which interferes with oral correction of hypoglycemia using carbohydrates. 1
  • This is a critical safety concern requiring patient education on alternative hypoglycemia management strategies.
  • Patients must understand that oral glucose may not effectively treat hypoglycemia while on SGLT-1 inhibitors. 1

Metabolic and Hormonal Effects

Incretin Hormone Alterations

  • SGLT-1 inhibition reduces glucose-dependent insulinotropic peptide (GIP) secretion, indicating downregulation of K cell secretion. 2
  • Conversely, GLP-1 and peptide YY (PYY) secretion are enhanced by SGLT-1 inhibition in humans. 2
  • These hormonal changes may contribute to both therapeutic effects and adverse event profiles. 2

Risk Stratification

Higher risk patients requiring closer monitoring:

  • Type 1 diabetes patients (baseline DKA risk already elevated). 4, 8
  • Patients undergoing surgery, especially emergency procedures (1.1% ketoacidosis incidence vs. 0.17% for elective surgery). 6
  • Patients with reduced kidney function (though dual inhibitors may maintain efficacy). 4
  • Non-diabetic patients taking SGLT inhibitors for heart failure (insufficient insulin to prevent ketosis). 6

Monitoring Requirements

  • Monitor blood glucose and ketone levels regularly, particularly during illness, fasting, or perioperative periods. 6, 7
  • Check capillary ketones before restarting SGLT inhibitors post-surgery (should be <0.6 mmol/L). 6
  • Assess hydration status and electrolytes, especially during gastrointestinal symptoms. 6, 7
  • Monitor for genital mycotic infections (increased risk with SGLT-2 component). 9, 8

Perioperative Management

  • Withhold SGLT inhibitors 3-4 days before scheduled surgery per American College of Cardiology/American Heart Association guidelines. 6, 7
  • UK guidelines suggest a less conservative approach (omit day before and day of procedure), but American guidelines are more cautious. 6
  • Restart only when patient is eating and drinking normally (usually 24-48 hours post-surgery) and ketones are <0.6 mmol/L. 6
  • Provide written sick-day rules at discharge. 6

Common Pitfalls to Avoid

  • Do not initiate SGLT inhibitors in patients on very low energy diets, as this already induces ketosis and combination could cause significant ketoacidosis. 6
  • Do not restart SGLT inhibitors too early post-operatively before normal oral intake is established. 6
  • Do not rely on oral glucose alone for hypoglycemia correction in patients on SGLT-1 inhibitors. 1
  • Do not ignore normal glucose levels when assessing for DKA—euglycemic DKA is the characteristic presentation. 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.